Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02444936
Other study ID # Canaday Zostavax
Secondary ID
Status Active, not recruiting
Phase Phase 4
First received May 7, 2015
Last updated April 5, 2018
Start date May 1, 2015
Est. completion date May 1, 2018

Study information

Verified date April 2018
Source Louis Stokes VA Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates if the shingles vaccine works in those persons that receive it before they receive chemotherapy for solid organ tumors. Half of the participants will receive the ZOSTAVAX shingle vaccine and half of the participants will not received anything.


Description:

This study is a single blind randomized clinical trial measuring the immunologic efficacy of ZOSTAVAX vs. no vaccine in 60 adults with solid organ tumors before, during and after chemotherapy. The personnel performing the laboratory studies will be blinded to vaccine vs. no vaccine. In a pilot study of an FDA approved vaccine that is being used within the parameters of the package insert and ACIP recommendations, placebo vaccine is not required to access our key primary immunologic endpoint.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 22
Est. completion date May 1, 2018
Est. primary completion date May 1, 2018
Accepts healthy volunteers No
Gender All
Age group 50 Years and older
Eligibility Inclusion Criteria:

- Solid organ tumor patients that have at least 14 days between entry into the study with ZOSTAVAX vaccination and initial therapy for their malignancy that will include chemotherapy alone or surgery with subsequent chemotherapy plus or minus radiation therapy

- A plan for chemotherapy that at the onset at least an anticipated stop date within 3-6 months of our sample collection phase of the study

Exclusion Criteria:

- Prior history of HZ or shingles vaccine

- Systemic chemotherapy < 3 months prior to enrollment

- Any history of hematologic malignancy, HIV/AIDS, hematopoietic stem cell transplant, or other cellular immunodeficiency state

- Those receiving immunomodulating drugs at the time of vaccination such as prednisone methotrexate, azathioprine, mercaptopurine, or other biologics including TNF-alpha inhibitors

- Widespread metastatic tumor with bone marrow involvement

- Indefinite duration palliative chemotherapy subjects

- Inability to communicate with the study staff or bring unable to consent for themselves

- History of anaphylactic/anaphylactiod reaction to gelatin, neomycin, or other components of the vaccine

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ZOSTAVAX
Shingles vaccine

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Louis Stokes VA Medical Center Duke University

Outcome

Type Measure Description Time frame Safety issue
Primary Measuring the Efficacy of ZOSTAVAX in Chemotherapy Patients (Changes in ZOSTAVAX-specific IFN-gamma Spot Forming Units Will be Measured by ELISPOT) To examine the cellular immunologic efficacy as measured by IFN-gamma assays of ZOSTAVAX given to individuals with solid organ tumors at least 14 days prior to initiation of chemotherapy or surgery and then chemotherapy. Changes in ZOSTAVAX-specific IFN-gamma spot forming units will be measured by ELISPOT. 3 years
Primary Measuring the Safety of ZOSTAVAX Given to Chemotherapy Patients (Vaccine Report Card (VRC) to Document Injection-site Adverse Experiences, Systemic Clinical Adverse Experiences (AEs), Concomitant Medications, and Oral Temperatures To asses the safety of ZOSTAVAX given to subjects that will receive chemotherapy or surgery and then chemotherapy for solid organ tumor at least 14 days after vaccination. Safety and tolerability data will be collected for all subjects throughout the study. Each subject will be given a Vaccine Report Card (VRC) to document injection-site adverse experiences, systemic clinical adverse experiences (AEs), concomitant medications, and oral temperatures (only if feeling feverish) noted during the 14-day post-vaccination period. Participants will be asked to notify the study personnel immediately if any unexpected or serious adverse experience (SAE) occurs. At all study visits subjects will be asked about any unreported SAEs. All AEs and SAEs will be recorded on an AE/SAE case report form and relationship to study vaccine will be determined by the site investigator. 3 years
See also
  Status Clinical Trial Phase
Completed NCT01132729 - Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions N/A
Completed NCT01132716 - Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions N/A
Completed NCT04099706 - Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT N/A
Completed NCT04540081 - Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and LivER Cancer N/A
Completed NCT01527370 - Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025) Phase 3
Completed NCT00534248 - Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022) Phase 3
Completed NCT01262300 - Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents Phase 1
Completed NCT00576108 - A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN) Phase 2
Completed NCT00109122 - Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007) Phase 2
Completed NCT04047979 - Systems Biology of Zoster Vaccine Phase 2
Active, not recruiting NCT05871541 - A First-in-Human Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine Phase 1
Completed NCT02114333 - Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds Phase 1
Completed NCT00900783 - A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster Phase 2
Completed NCT01600079 - ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)
Recruiting NCT05554068 - Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Phase 2
Recruiting NCT06238726 - Nudging Patients to Increase Shingles Vaccination N/A
Completed NCT02704572 - Optimal Timing of Zoster Vaccine After Zoster Illness N/A
Completed NCT00300222 - Study of NGX-4010 for the Treatment of Postherpetic Neuralgia Phase 3
Terminated NCT02412917 - A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia Phase 3
Completed NCT00115310 - Study of NGX-4010 for the Treatment of Postherpetic Neuralgia Phase 3